(Q44280775)

English

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

retracted scientific article published in January 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

based on heuristic

inferred from title

author name string

Naoyuki Nakao

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ashio Yoshimura

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Hiroyuki Morita

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Masyuki Takada

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Tsuguo Kayano

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Terukuni Ideura

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

361

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

9352

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

117-124

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression, remission, regression of chronic renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term comparison between captopril and nifedipine in the progression of renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Add-on angiotensin receptor blockade with maximized ACE inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912229-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(03)12229-5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44280775&oldid=2109108505"